The given study focuses on the evaluation of the psycho-emotional well-being of patients with non-Hodgkin’s lymphomas (NHL) according to age, gender, living environment, morphological subtype, stage, ...primary tumor focus, Charlson comorbiditiesindex, and completion of first-line chemotherapy treatment. To carry out the study, a number of 126 patients aged between 18 and 78 years, included in the treatment and monitored in the Department of Hematology, IMSP Oncological Institute, during the years 2020-2022, were selected. The Global Well Being (GWB) score was used to test the proposed hypotheses. The results illustrate statistically significant correlations between GWB score and gender, living environment, extranodal onset, and treatment period. The lack of statistically significant correlations was appreciated between the GWB score and age, disease stage, comorbidities.
Limfoamele non-Hodgkin (LNH) includ un grup de tumori maligne ale ţesutului limfatic, constituind cele mai frecvente hemopatii maligne. Tratamentul modern al LNH permit obținerea remisiunii complete, ...prelungirea duratei de viață al pacienților. În pofida tuturor celor de mai sus, modifi cările psihofi ziologice și emoționale cauzate de această boală pot persista timp îndelungat după finalizarea tratamentului specific. Obținerea remisiunii complete și supraviețuirea pacientului sunt principalele criterii pentru evaluarea rezultatelor tratamentului LNH, dar ele nu reflectă bunăstarea psihologică și emoțională al pacientului cu proces limfoproliferativ. Evaluarea calității vieții psihoemoționale al pacienților primari cu LNH este necesară și poate fi efectuată prin estimarea stării psihologice de bine, care s-a reliefat în rezultatele grupului de studiu GWB (Global Well Being). Informația obținută de la pacient, din acest chestionar, deși este subiectivă, contează la luarea deciziilor în conduita medicală și în recuperarea complexă, ulterioară. Lucrarea dată își propune evaluarea bunăstării psihologice al pacienților primari cu LNH, conform indicelui de bunăstare psihologică generală în funcție de vârstă, sex, tipul morfologic al limfomului malign și gradul de răspândire al procesului tumoral.
Non-Hodgkin’s lymphomas (NHL) include a group of malignant tumors of lymphatictissue, constituting the most common malignant hematological diseases. ModernNHL treatment allows for complete remission, ...prolonging the life of patients. Despiteall of the above, the psychophysiological and emotional changes caused by this diseasecan persist for a long time after fi nishing the specifi c treatment. Complete remission andpatient survival are the main criteria for evaluating NHL treatment outcomes, but theydo not refl ect the psychological and emotional well-being of the patient with lymphoproliferativemalignancy. The evaluation of the psycho-emotional quality of life of primarypatients with NHL is necessary and can be performed by estimating the psychologicalwell-being, which was highlighted in the results of the GWB (Global Well Being) studygroup. The information obtained from the patient, from this questionnaire, although itis subjective, counts when making decisions in medical conduct and in the complex,subsequent recovery. This paper aims to assess the psychological well-being of primarypatients with NHL according to the index of general psychological well-being dependingon age, sex, morphological type of malignant lymphoma and the degree of spreadof the tumor process.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy and a heterogeneous entity comprised of several biologically distinct subtypes. Recently, novel genetic classifications of ...DLBCL have been resolved based on common mutational patterns indicative of distinct pathways of transformation. However, the complicated and costly nature of the novel classifiers has precluded their inclusion into routine practice. In view of this, the status of the TP53 gene, which is mutated or deleted in 20–30% of the cases, has emerged as an important prognostic factor for DLBCL patients, setting itself apart from other predictors. TP53 genetic lesions are particularly enriched in a genetic subtype of DLBCL that shares genomic features with Richter Syndrome, highlighting the possibility of a subset of DLBCL arising from the transformation of an occult chronic lymphocytic leukemia-like malignancy, such as monoclonal B-cell lymphocytosis. Patients with TP53-mutated DLBCL, including those with Richter Syndrome, have a particularly poor prognosis and display inferior responses to standard chemoimmunotherapy regimens. The data presented in this manuscript argue for the need for improved and more practical risk-stratification models for patients with DLBCL and show the potential for the use of TP53 mutational status for prognostication and, in prospect, treatment stratification in DLBCL.
Next generation sequencing (NGS) is a technology that broadens the horizon of knowledge of several somatic pathologies, especially in oncological and oncohematological pathology. In the case of NHL, ...the understanding of the mechanisms of tumorigenesis, tumor proliferation and the identification of genetic markers specific to different lymphoma subtypes led to more accurate classification and diagnosis. Similarly, the data obtained through NGS allowed the identification of recurrent somatic mutations that can serve as therapeutic targets that can be inhibited and thus reducing the rate of resistant cases. The article’s purpose is to offer a comprehensive overview of the best ways of integrating of next-generation sequencing technologies for diagnosis, prognosis, classification, and selection of optimal therapy from the perspective of tailor-made medicine.
Background: Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative, monoclonal, indolent hemopathy characterized by pathologically increased synthesis of mature but immunologically ...dysfunctional B lymphocytes. CLL is considered the pathology of the adult with comorbidities, whose average age is 55 years, who is integrated into the work field. Despite advances in the field of medicine, CLL remains an incurable disease, but the use of targeted, personalized therapy with new agents’ conditions not only increases the life span, but also improves the of quality life of these patients, ensuring social, family and professional integration. This fact presents a favourable socioeconomic impact, a valuable indicator especially in countries with a low and medium socio-demographic index. The identification of biomarkers and the advent of personalized therapies have transformed the way the disease is treated and changed the lives and quality of life of CLL patients. Conclusions: CLL remains a current medical and socioeconomic problem, and the behaviour of patients with CLL remains a challenge for the health system in the Republic of Moldova. The implementation of cyto-genetic and molecular-biological diagnosis is important for the stratification of patients, the selection of optimal targeted therapy. CLL comorbidity is an independent indicator of treatment response, predisposes to adverse drug effects and reduces the quality of life of CLL patients. The individual approach to the patient with CLL, the administration of therapy according to international guidelines will give patients better chances of survival and a longer plateau of stabilization.
Key Clinical Message
Identifying myeloid sarcoma in rare locations is a diagnostic challenge and requires careful evaluation. The optimal management of extramedullary disease requires further ...investigation, but tissue biopsy and a personalized approach are crucial.
Herein, we describe an unusual case of acute myeloid leukemia presenting with an isolated involvement of the temporal bone after a complete remission of systemic disease for more than a year. The clinical, radiological, and pathological features are discussed, highlighting the importance of considering differential diagnoses and appropriate management.
A computed tomography scan reveals a complete homogenous left‐sided and partial right‐sided opacification of the mastoid cells and the middle ear with a relatively intact bony structure and no distinct masses.
Non-Hodgkin's lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. They are one of the most common malignancies and they represent one of the most complicated problems of ...oncohematology. The age group that is mostly affected by NHL in the Republic of Moldova is the patients over 60 years, and the disorder in most cases starts in lymph nodes. This study aims to determine the particularities of elderly patients with NHL with primary involvement of peripheral lymph nodes(l/n).
A retrospective study of a group of 78 NHL patients with primary lymph node involvement was performed. The average age of study participants ranged from 60 to 84 years.
NHL more often developed primarily in the peripheral l/n (84.7%), less frequently in the mediastinal l/n (6.4%) and abdominal l/n(8.9%). Aggressive NHL predominated (59.0%), but indolent NHL also developed quite frequently (41.0%), which were more frequent in cases of primary affection to the cervical l/n (47.4%), inguinal l/n(41.7%), and abdominal l/n(42.9%). The 5-year survival of NHL patients with primary lymph node involvement aged over 60 years was low and amounted to 31.2%;
NHL occurred more often in the peripheral lymph nodes (84.7%), less frequently in the mediastinum (6.4%), and abdominal lymph nodes (8.9%). The frequency of aggressive NHL was 59.0%. Indolent NHL was diagnosed in 41% of cases. The 5-year survival rate in the study group constitutes 31,2%, lower compared with younger patients treated in the same center.
ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA Buruiana, Sanda; Mazur, Minodora; Robu, Maria ...
Hematology, Transfusion and Cell Therapy,
November 2021, 2021-11-00, 2021-11-01, Letnik:
43
Journal Article
Recenzirano
Odprti dostop
Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL).
The study included 83 patients (men-34, women-49) with a mean age of 63.2 ...years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; antiβ2glycoprotein I IgG, IgM and aCL antibodies, by ELISA method. Hemostasis disorders were evaluated according to the type of NHL, stage, tumor size.
aCL were detected in 10 (12%) patients: 6 patients with aggressive type lymphoma and 4 patients with indolent type lymphoma, with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies (10%) and antiβ2glycoprotein I IgG (10%). Hemostasis disorders were found in 6 (60%) patients: thrombotic events-at 4 (40%) patients with Mantle cell lymphoma (1 patient), Small lymphocytic lymphoma (1 patient), lymphoblastic lymphoma (2 patients). Local stage (I and II) of the lymphoma was in 75%, but with a large size of the tumor (> 11 cm), and hemorrhage at 2 (20%) patients with stage IV Small lymphocytic lymphoma, in which immune thrombocytopenia developed.
The presence of antiphospholipid antibodies, in particular of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis diseases in NHL patients, especially thrombosis.
PDF